Global COVID-19 CRISPR Technology Market
Global COVID-19 CRISPR Technology Market

COVID-19 CRISPR Technology Comprehensive Study by Type (Enzymes, Kits, GRNA, Libraries, Design Tools), End-users (Pharma & Biopharma Companies, Academics, CROs), Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), Service (GRNA Design, Cell Line Engineering) Players and Region - Global Market Outlook to 2025

COVID-19 CRISPR Technology Market Segmented into XX Submarkets. | Forecast Years: 2020- 2025  

Jun 2020 Edition 200 Pages 213 Tables & Figures
  • Summary
  • Market Segments
  • Table of Content
  • List of Tables & Figures
  • Companies Mentioned
Scope of the Study

CRISPR technology is a simple yet powerful tool for editing genomes can be used in the COVID-19. This technology allows researchers to easily alter DNA sequences and modify gene function. With the use of this technology kits the coronavirus can be detected in approximately one hour. Recently U.S. Food and Drug Administration (FDA) has approved Sherlock Biosciences Company's Sherlock CRISPR SARS-CoV-2 kit for the detection of the virus that causes COVID-19, providing results in approximately one hour. These kits are designed for use in laboratories certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA), 42 U.S.C. 263a, to perform high complexity tests.

The market study is being classified by Type (Enzymes, Kits, gRNA, Libraries and Design Tools) and major geographies with country level break-up.

Thermo Fisher Scientific (United States), Merck KGaA (Germany), Genscript Biotech (United States), Integrated DNA Technologies, Inc. (United States), Horizon Discovery Group (United Kingdom), Agilent Technologies (United States), Cellecta, Inc. (United States), GeneCopoeia, Inc. (United States), New England Biolabs (United States) and Origene Technologies, Inc. (United States) are some of the key players profiled in the study. Additionally, the Players which are also part of the research are Synthego Corporation (United States) and Toolgen, Inc. (South Korea).

The companies are exploring the market by adopting expansions, investments, new service launches and collaborations as their preferred strategies. The players are exploring new geographies through expansions and acquisitions across the globe to gain competitive advantage through combined collaborations. Research Analyst at AMA predicts that United States Players will contribute to the maximum growth of Global COVID-19 CRISPR Technology market throughout the predicted period.

Segment Analysis
AdvanceMarketAnalytics has segmented the market of Global COVID-19 CRISPR Technology market by Type, Application and Region.

On the basis of geography, the market of COVID-19 CRISPR Technology has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.

Market Drivers
  • Increased Number of Deaths Associated with COVID-19
  • Growing Focus on Development of Gene Therapeutics
  • High Investments by the Major Players in the Market

Market Trend
  • High Demand for Diagnostics Kits for Early Detection of COVID-19
  • Increased Government Funding for Research and Development

Restraints
  • High-Cost Associated with CRISPER Technology Test Kits
  • Shortages of Kits due to High Demand

Opportunities
  • Growing Demand for Diagnostic Kits with Increasing COVID-19 Cases Worldwide
  • Increasing Demand for Cure of COVID-19
  • Growth in the Health Care Industry

Challenges
  • Stringent Government Rules and Regulations





Key Target Audience
COVID-19 CRISPR Technology Manufacturers, Raw Material Suppliers, Distributors, Emerging Companies and End-users

Customization in the Report Available:
The Study can be customized to meet your requirements. Please connect with our representative, who will ensure you get a report that suits your needs.
Data related to EXIM [Export- Import], production & consumption by country or regional level break-up can be provided based on client request**
** Confirmation on availability of data would be informed prior purchase
Report Objectives / Segmentation Covered
By Type
  • Enzymes
  • Kits
  • gRNA
  • Libraries
  • Design Tools
By End-users
  • Pharma & Biopharma Companies
  • Academics
  • CROs

By Distribution Channel
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

By Service
  • GRNA Design
  • Cell Line Engineering

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Increased Number of Deaths Associated with COVID-19
      • 3.2.2. Growing Focus on Development of Gene Therapeutics
      • 3.2.3. High Investments by the Major Players in the Market
    • 3.3. Market Challenges
      • 3.3.1. Stringent Government Rules and Regulations
    • 3.4. Market Trends
      • 3.4.1. High Demand for Diagnostics Kits for Early Detection of COVID-19
      • 3.4.2. Increased Government Funding for Research and Development
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global COVID-19 CRISPR Technology, by Type, End-users, Distribution Channel, Service and Region (value) (2014-2019)
    • 5.1. Introduction
    • 5.2. Global COVID-19 CRISPR Technology (Value)
      • 5.2.1. Global COVID-19 CRISPR Technology by: Type (Value)
        • 5.2.1.1. Enzymes
        • 5.2.1.2. Kits
        • 5.2.1.3. GRNA
        • 5.2.1.4. Libraries
        • 5.2.1.5. Design Tools
      • 5.2.2. Global COVID-19 CRISPR Technology by: End-users (Value)
        • 5.2.2.1. Pharma & Biopharma Companies
        • 5.2.2.2. Academics
        • 5.2.2.3. CROs
      • 5.2.3. Global COVID-19 CRISPR Technology by: Distribution Channel (Value)
        • 5.2.3.1. Hospital Pharmacies
        • 5.2.3.2. Retail Pharmacies
        • 5.2.3.3. Online Pharmacies
      • 5.2.4. Global COVID-19 CRISPR Technology by: Service (Value)
        • 5.2.4.1. GRNA Design
        • 5.2.4.2. Cell Line Engineering
      • 5.2.5. Global COVID-19 CRISPR Technology Region
        • 5.2.5.1. South America
          • 5.2.5.1.1. Brazil
          • 5.2.5.1.2. Argentina
          • 5.2.5.1.3. Rest of South America
        • 5.2.5.2. Asia Pacific
          • 5.2.5.2.1. China
          • 5.2.5.2.2. Japan
          • 5.2.5.2.3. India
          • 5.2.5.2.4. South Korea
          • 5.2.5.2.5. Taiwan
          • 5.2.5.2.6. Australia
          • 5.2.5.2.7. Rest of Asia-Pacific
        • 5.2.5.3. Europe
          • 5.2.5.3.1. Germany
          • 5.2.5.3.2. France
          • 5.2.5.3.3. Italy
          • 5.2.5.3.4. United Kingdom
          • 5.2.5.3.5. Netherlands
          • 5.2.5.3.6. Rest of Europe
        • 5.2.5.4. MEA
          • 5.2.5.4.1. Middle East
          • 5.2.5.4.2. Africa
        • 5.2.5.5. North America
          • 5.2.5.5.1. United States
          • 5.2.5.5.2. Canada
          • 5.2.5.5.3. Mexico
  • 6. COVID-19 CRISPR Technology: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2019)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Thermo Fisher Scientific (United States)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Merck KGaA (Germany)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Genscript Biotech (United States)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Integrated DNA Technologies, Inc. (United States)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Horizon Discovery Group (United Kingdom)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Agilent Technologies (United States)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Cellecta, Inc. (United States)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. GeneCopoeia, Inc. (United States)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. New England Biolabs (United States)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Origene Technologies, Inc. (United States)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
  • 7. Global COVID-19 CRISPR Technology Sale, by Type, End-users, Distribution Channel, Service and Region (value) (2020-2025)
    • 7.1. Introduction
    • 7.2. Global COVID-19 CRISPR Technology (Value)
      • 7.2.1. Global COVID-19 CRISPR Technology by: Type (Value)
        • 7.2.1.1. Enzymes
        • 7.2.1.2. Kits
        • 7.2.1.3. GRNA
        • 7.2.1.4. Libraries
        • 7.2.1.5. Design Tools
      • 7.2.2. Global COVID-19 CRISPR Technology by: End-users (Value)
        • 7.2.2.1. Pharma & Biopharma Companies
        • 7.2.2.2. Academics
        • 7.2.2.3. CROs
      • 7.2.3. Global COVID-19 CRISPR Technology by: Distribution Channel (Value)
        • 7.2.3.1. Hospital Pharmacies
        • 7.2.3.2. Retail Pharmacies
        • 7.2.3.3. Online Pharmacies
      • 7.2.4. Global COVID-19 CRISPR Technology by: Service (Value)
        • 7.2.4.1. GRNA Design
        • 7.2.4.2. Cell Line Engineering
      • 7.2.5. Global COVID-19 CRISPR Technology Region
        • 7.2.5.1. South America
          • 7.2.5.1.1. Brazil
          • 7.2.5.1.2. Argentina
          • 7.2.5.1.3. Rest of South America
        • 7.2.5.2. Asia Pacific
          • 7.2.5.2.1. China
          • 7.2.5.2.2. Japan
          • 7.2.5.2.3. India
          • 7.2.5.2.4. South Korea
          • 7.2.5.2.5. Taiwan
          • 7.2.5.2.6. Australia
          • 7.2.5.2.7. Rest of Asia-Pacific
        • 7.2.5.3. Europe
          • 7.2.5.3.1. Germany
          • 7.2.5.3.2. France
          • 7.2.5.3.3. Italy
          • 7.2.5.3.4. United Kingdom
          • 7.2.5.3.5. Netherlands
          • 7.2.5.3.6. Rest of Europe
        • 7.2.5.4. MEA
          • 7.2.5.4.1. Middle East
          • 7.2.5.4.2. Africa
        • 7.2.5.5. North America
          • 7.2.5.5.1. United States
          • 7.2.5.5.2. Canada
          • 7.2.5.5.3. Mexico
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. COVID-19 CRISPR Technology: by Type(USD Million)
  • Table 2. COVID-19 CRISPR Technology Enzymes , by Region USD Million (2014-2019)
  • Table 3. COVID-19 CRISPR Technology Kits , by Region USD Million (2014-2019)
  • Table 4. COVID-19 CRISPR Technology GRNA , by Region USD Million (2014-2019)
  • Table 5. COVID-19 CRISPR Technology Libraries , by Region USD Million (2014-2019)
  • Table 6. COVID-19 CRISPR Technology Design Tools , by Region USD Million (2014-2019)
  • Table 7. COVID-19 CRISPR Technology: by End-users(USD Million)
  • Table 8. COVID-19 CRISPR Technology Pharma & Biopharma Companies , by Region USD Million (2014-2019)
  • Table 9. COVID-19 CRISPR Technology Academics , by Region USD Million (2014-2019)
  • Table 10. COVID-19 CRISPR Technology CROs , by Region USD Million (2014-2019)
  • Table 11. COVID-19 CRISPR Technology: by Distribution Channel(USD Million)
  • Table 12. COVID-19 CRISPR Technology Hospital Pharmacies , by Region USD Million (2014-2019)
  • Table 13. COVID-19 CRISPR Technology Retail Pharmacies , by Region USD Million (2014-2019)
  • Table 14. COVID-19 CRISPR Technology Online Pharmacies , by Region USD Million (2014-2019)
  • Table 15. COVID-19 CRISPR Technology: by Service(USD Million)
  • Table 16. COVID-19 CRISPR Technology GRNA Design , by Region USD Million (2014-2019)
  • Table 17. COVID-19 CRISPR Technology Cell Line Engineering , by Region USD Million (2014-2019)
  • Table 18. South America COVID-19 CRISPR Technology, by Country USD Million (2014-2019)
  • Table 19. South America COVID-19 CRISPR Technology, by Type USD Million (2014-2019)
  • Table 20. South America COVID-19 CRISPR Technology, by End-users USD Million (2014-2019)
  • Table 21. South America COVID-19 CRISPR Technology, by Distribution Channel USD Million (2014-2019)
  • Table 22. South America COVID-19 CRISPR Technology, by Service USD Million (2014-2019)
  • Table 23. Brazil COVID-19 CRISPR Technology, by Type USD Million (2014-2019)
  • Table 24. Brazil COVID-19 CRISPR Technology, by End-users USD Million (2014-2019)
  • Table 25. Brazil COVID-19 CRISPR Technology, by Distribution Channel USD Million (2014-2019)
  • Table 26. Brazil COVID-19 CRISPR Technology, by Service USD Million (2014-2019)
  • Table 27. Argentina COVID-19 CRISPR Technology, by Type USD Million (2014-2019)
  • Table 28. Argentina COVID-19 CRISPR Technology, by End-users USD Million (2014-2019)
  • Table 29. Argentina COVID-19 CRISPR Technology, by Distribution Channel USD Million (2014-2019)
  • Table 30. Argentina COVID-19 CRISPR Technology, by Service USD Million (2014-2019)
  • Table 31. Rest of South America COVID-19 CRISPR Technology, by Type USD Million (2014-2019)
  • Table 32. Rest of South America COVID-19 CRISPR Technology, by End-users USD Million (2014-2019)
  • Table 33. Rest of South America COVID-19 CRISPR Technology, by Distribution Channel USD Million (2014-2019)
  • Table 34. Rest of South America COVID-19 CRISPR Technology, by Service USD Million (2014-2019)
  • Table 35. Asia Pacific COVID-19 CRISPR Technology, by Country USD Million (2014-2019)
  • Table 36. Asia Pacific COVID-19 CRISPR Technology, by Type USD Million (2014-2019)
  • Table 37. Asia Pacific COVID-19 CRISPR Technology, by End-users USD Million (2014-2019)
  • Table 38. Asia Pacific COVID-19 CRISPR Technology, by Distribution Channel USD Million (2014-2019)
  • Table 39. Asia Pacific COVID-19 CRISPR Technology, by Service USD Million (2014-2019)
  • Table 40. China COVID-19 CRISPR Technology, by Type USD Million (2014-2019)
  • Table 41. China COVID-19 CRISPR Technology, by End-users USD Million (2014-2019)
  • Table 42. China COVID-19 CRISPR Technology, by Distribution Channel USD Million (2014-2019)
  • Table 43. China COVID-19 CRISPR Technology, by Service USD Million (2014-2019)
  • Table 44. Japan COVID-19 CRISPR Technology, by Type USD Million (2014-2019)
  • Table 45. Japan COVID-19 CRISPR Technology, by End-users USD Million (2014-2019)
  • Table 46. Japan COVID-19 CRISPR Technology, by Distribution Channel USD Million (2014-2019)
  • Table 47. Japan COVID-19 CRISPR Technology, by Service USD Million (2014-2019)
  • Table 48. India COVID-19 CRISPR Technology, by Type USD Million (2014-2019)
  • Table 49. India COVID-19 CRISPR Technology, by End-users USD Million (2014-2019)
  • Table 50. India COVID-19 CRISPR Technology, by Distribution Channel USD Million (2014-2019)
  • Table 51. India COVID-19 CRISPR Technology, by Service USD Million (2014-2019)
  • Table 52. South Korea COVID-19 CRISPR Technology, by Type USD Million (2014-2019)
  • Table 53. South Korea COVID-19 CRISPR Technology, by End-users USD Million (2014-2019)
  • Table 54. South Korea COVID-19 CRISPR Technology, by Distribution Channel USD Million (2014-2019)
  • Table 55. South Korea COVID-19 CRISPR Technology, by Service USD Million (2014-2019)
  • Table 56. Taiwan COVID-19 CRISPR Technology, by Type USD Million (2014-2019)
  • Table 57. Taiwan COVID-19 CRISPR Technology, by End-users USD Million (2014-2019)
  • Table 58. Taiwan COVID-19 CRISPR Technology, by Distribution Channel USD Million (2014-2019)
  • Table 59. Taiwan COVID-19 CRISPR Technology, by Service USD Million (2014-2019)
  • Table 60. Australia COVID-19 CRISPR Technology, by Type USD Million (2014-2019)
  • Table 61. Australia COVID-19 CRISPR Technology, by End-users USD Million (2014-2019)
  • Table 62. Australia COVID-19 CRISPR Technology, by Distribution Channel USD Million (2014-2019)
  • Table 63. Australia COVID-19 CRISPR Technology, by Service USD Million (2014-2019)
  • Table 64. Rest of Asia-Pacific COVID-19 CRISPR Technology, by Type USD Million (2014-2019)
  • Table 65. Rest of Asia-Pacific COVID-19 CRISPR Technology, by End-users USD Million (2014-2019)
  • Table 66. Rest of Asia-Pacific COVID-19 CRISPR Technology, by Distribution Channel USD Million (2014-2019)
  • Table 67. Rest of Asia-Pacific COVID-19 CRISPR Technology, by Service USD Million (2014-2019)
  • Table 68. Europe COVID-19 CRISPR Technology, by Country USD Million (2014-2019)
  • Table 69. Europe COVID-19 CRISPR Technology, by Type USD Million (2014-2019)
  • Table 70. Europe COVID-19 CRISPR Technology, by End-users USD Million (2014-2019)
  • Table 71. Europe COVID-19 CRISPR Technology, by Distribution Channel USD Million (2014-2019)
  • Table 72. Europe COVID-19 CRISPR Technology, by Service USD Million (2014-2019)
  • Table 73. Germany COVID-19 CRISPR Technology, by Type USD Million (2014-2019)
  • Table 74. Germany COVID-19 CRISPR Technology, by End-users USD Million (2014-2019)
  • Table 75. Germany COVID-19 CRISPR Technology, by Distribution Channel USD Million (2014-2019)
  • Table 76. Germany COVID-19 CRISPR Technology, by Service USD Million (2014-2019)
  • Table 77. France COVID-19 CRISPR Technology, by Type USD Million (2014-2019)
  • Table 78. France COVID-19 CRISPR Technology, by End-users USD Million (2014-2019)
  • Table 79. France COVID-19 CRISPR Technology, by Distribution Channel USD Million (2014-2019)
  • Table 80. France COVID-19 CRISPR Technology, by Service USD Million (2014-2019)
  • Table 81. Italy COVID-19 CRISPR Technology, by Type USD Million (2014-2019)
  • Table 82. Italy COVID-19 CRISPR Technology, by End-users USD Million (2014-2019)
  • Table 83. Italy COVID-19 CRISPR Technology, by Distribution Channel USD Million (2014-2019)
  • Table 84. Italy COVID-19 CRISPR Technology, by Service USD Million (2014-2019)
  • Table 85. United Kingdom COVID-19 CRISPR Technology, by Type USD Million (2014-2019)
  • Table 86. United Kingdom COVID-19 CRISPR Technology, by End-users USD Million (2014-2019)
  • Table 87. United Kingdom COVID-19 CRISPR Technology, by Distribution Channel USD Million (2014-2019)
  • Table 88. United Kingdom COVID-19 CRISPR Technology, by Service USD Million (2014-2019)
  • Table 89. Netherlands COVID-19 CRISPR Technology, by Type USD Million (2014-2019)
  • Table 90. Netherlands COVID-19 CRISPR Technology, by End-users USD Million (2014-2019)
  • Table 91. Netherlands COVID-19 CRISPR Technology, by Distribution Channel USD Million (2014-2019)
  • Table 92. Netherlands COVID-19 CRISPR Technology, by Service USD Million (2014-2019)
  • Table 93. Rest of Europe COVID-19 CRISPR Technology, by Type USD Million (2014-2019)
  • Table 94. Rest of Europe COVID-19 CRISPR Technology, by End-users USD Million (2014-2019)
  • Table 95. Rest of Europe COVID-19 CRISPR Technology, by Distribution Channel USD Million (2014-2019)
  • Table 96. Rest of Europe COVID-19 CRISPR Technology, by Service USD Million (2014-2019)
  • Table 97. MEA COVID-19 CRISPR Technology, by Country USD Million (2014-2019)
  • Table 98. MEA COVID-19 CRISPR Technology, by Type USD Million (2014-2019)
  • Table 99. MEA COVID-19 CRISPR Technology, by End-users USD Million (2014-2019)
  • Table 100. MEA COVID-19 CRISPR Technology, by Distribution Channel USD Million (2014-2019)
  • Table 101. MEA COVID-19 CRISPR Technology, by Service USD Million (2014-2019)
  • Table 102. Middle East COVID-19 CRISPR Technology, by Type USD Million (2014-2019)
  • Table 103. Middle East COVID-19 CRISPR Technology, by End-users USD Million (2014-2019)
  • Table 104. Middle East COVID-19 CRISPR Technology, by Distribution Channel USD Million (2014-2019)
  • Table 105. Middle East COVID-19 CRISPR Technology, by Service USD Million (2014-2019)
  • Table 106. Africa COVID-19 CRISPR Technology, by Type USD Million (2014-2019)
  • Table 107. Africa COVID-19 CRISPR Technology, by End-users USD Million (2014-2019)
  • Table 108. Africa COVID-19 CRISPR Technology, by Distribution Channel USD Million (2014-2019)
  • Table 109. Africa COVID-19 CRISPR Technology, by Service USD Million (2014-2019)
  • Table 110. North America COVID-19 CRISPR Technology, by Country USD Million (2014-2019)
  • Table 111. North America COVID-19 CRISPR Technology, by Type USD Million (2014-2019)
  • Table 112. North America COVID-19 CRISPR Technology, by End-users USD Million (2014-2019)
  • Table 113. North America COVID-19 CRISPR Technology, by Distribution Channel USD Million (2014-2019)
  • Table 114. North America COVID-19 CRISPR Technology, by Service USD Million (2014-2019)
  • Table 115. United States COVID-19 CRISPR Technology, by Type USD Million (2014-2019)
  • Table 116. United States COVID-19 CRISPR Technology, by End-users USD Million (2014-2019)
  • Table 117. United States COVID-19 CRISPR Technology, by Distribution Channel USD Million (2014-2019)
  • Table 118. United States COVID-19 CRISPR Technology, by Service USD Million (2014-2019)
  • Table 119. Canada COVID-19 CRISPR Technology, by Type USD Million (2014-2019)
  • Table 120. Canada COVID-19 CRISPR Technology, by End-users USD Million (2014-2019)
  • Table 121. Canada COVID-19 CRISPR Technology, by Distribution Channel USD Million (2014-2019)
  • Table 122. Canada COVID-19 CRISPR Technology, by Service USD Million (2014-2019)
  • Table 123. Mexico COVID-19 CRISPR Technology, by Type USD Million (2014-2019)
  • Table 124. Mexico COVID-19 CRISPR Technology, by End-users USD Million (2014-2019)
  • Table 125. Mexico COVID-19 CRISPR Technology, by Distribution Channel USD Million (2014-2019)
  • Table 126. Mexico COVID-19 CRISPR Technology, by Service USD Million (2014-2019)
  • Table 127. Company Basic Information, Sales Area and Its Competitors
  • Table 128. Company Basic Information, Sales Area and Its Competitors
  • Table 129. Company Basic Information, Sales Area and Its Competitors
  • Table 130. Company Basic Information, Sales Area and Its Competitors
  • Table 131. Company Basic Information, Sales Area and Its Competitors
  • Table 132. Company Basic Information, Sales Area and Its Competitors
  • Table 133. Company Basic Information, Sales Area and Its Competitors
  • Table 134. Company Basic Information, Sales Area and Its Competitors
  • Table 135. Company Basic Information, Sales Area and Its Competitors
  • Table 136. Company Basic Information, Sales Area and Its Competitors
  • Table 137. COVID-19 CRISPR Technology: by Type(USD Million)
  • Table 138. COVID-19 CRISPR Technology Enzymes , by Region USD Million (2020-2025)
  • Table 139. COVID-19 CRISPR Technology Kits , by Region USD Million (2020-2025)
  • Table 140. COVID-19 CRISPR Technology GRNA , by Region USD Million (2020-2025)
  • Table 141. COVID-19 CRISPR Technology Libraries , by Region USD Million (2020-2025)
  • Table 142. COVID-19 CRISPR Technology Design Tools , by Region USD Million (2020-2025)
  • Table 143. COVID-19 CRISPR Technology: by End-users(USD Million)
  • Table 144. COVID-19 CRISPR Technology Pharma & Biopharma Companies , by Region USD Million (2020-2025)
  • Table 145. COVID-19 CRISPR Technology Academics , by Region USD Million (2020-2025)
  • Table 146. COVID-19 CRISPR Technology CROs , by Region USD Million (2020-2025)
  • Table 147. COVID-19 CRISPR Technology: by Distribution Channel(USD Million)
  • Table 148. COVID-19 CRISPR Technology Hospital Pharmacies , by Region USD Million (2020-2025)
  • Table 149. COVID-19 CRISPR Technology Retail Pharmacies , by Region USD Million (2020-2025)
  • Table 150. COVID-19 CRISPR Technology Online Pharmacies , by Region USD Million (2020-2025)
  • Table 151. COVID-19 CRISPR Technology: by Service(USD Million)
  • Table 152. COVID-19 CRISPR Technology GRNA Design , by Region USD Million (2020-2025)
  • Table 153. COVID-19 CRISPR Technology Cell Line Engineering , by Region USD Million (2020-2025)
  • Table 154. South America COVID-19 CRISPR Technology, by Country USD Million (2020-2025)
  • Table 155. South America COVID-19 CRISPR Technology, by Type USD Million (2020-2025)
  • Table 156. South America COVID-19 CRISPR Technology, by End-users USD Million (2020-2025)
  • Table 157. South America COVID-19 CRISPR Technology, by Distribution Channel USD Million (2020-2025)
  • Table 158. South America COVID-19 CRISPR Technology, by Service USD Million (2020-2025)
  • Table 159. Brazil COVID-19 CRISPR Technology, by Type USD Million (2020-2025)
  • Table 160. Brazil COVID-19 CRISPR Technology, by End-users USD Million (2020-2025)
  • Table 161. Brazil COVID-19 CRISPR Technology, by Distribution Channel USD Million (2020-2025)
  • Table 162. Brazil COVID-19 CRISPR Technology, by Service USD Million (2020-2025)
  • Table 163. Argentina COVID-19 CRISPR Technology, by Type USD Million (2020-2025)
  • Table 164. Argentina COVID-19 CRISPR Technology, by End-users USD Million (2020-2025)
  • Table 165. Argentina COVID-19 CRISPR Technology, by Distribution Channel USD Million (2020-2025)
  • Table 166. Argentina COVID-19 CRISPR Technology, by Service USD Million (2020-2025)
  • Table 167. Rest of South America COVID-19 CRISPR Technology, by Type USD Million (2020-2025)
  • Table 168. Rest of South America COVID-19 CRISPR Technology, by End-users USD Million (2020-2025)
  • Table 169. Rest of South America COVID-19 CRISPR Technology, by Distribution Channel USD Million (2020-2025)
  • Table 170. Rest of South America COVID-19 CRISPR Technology, by Service USD Million (2020-2025)
  • Table 171. Asia Pacific COVID-19 CRISPR Technology, by Country USD Million (2020-2025)
  • Table 172. Asia Pacific COVID-19 CRISPR Technology, by Type USD Million (2020-2025)
  • Table 173. Asia Pacific COVID-19 CRISPR Technology, by End-users USD Million (2020-2025)
  • Table 174. Asia Pacific COVID-19 CRISPR Technology, by Distribution Channel USD Million (2020-2025)
  • Table 175. Asia Pacific COVID-19 CRISPR Technology, by Service USD Million (2020-2025)
  • Table 176. China COVID-19 CRISPR Technology, by Type USD Million (2020-2025)
  • Table 177. China COVID-19 CRISPR Technology, by End-users USD Million (2020-2025)
  • Table 178. China COVID-19 CRISPR Technology, by Distribution Channel USD Million (2020-2025)
  • Table 179. China COVID-19 CRISPR Technology, by Service USD Million (2020-2025)
  • Table 180. Japan COVID-19 CRISPR Technology, by Type USD Million (2020-2025)
  • Table 181. Japan COVID-19 CRISPR Technology, by End-users USD Million (2020-2025)
  • Table 182. Japan COVID-19 CRISPR Technology, by Distribution Channel USD Million (2020-2025)
  • Table 183. Japan COVID-19 CRISPR Technology, by Service USD Million (2020-2025)
  • Table 184. India COVID-19 CRISPR Technology, by Type USD Million (2020-2025)
  • Table 185. India COVID-19 CRISPR Technology, by End-users USD Million (2020-2025)
  • Table 186. India COVID-19 CRISPR Technology, by Distribution Channel USD Million (2020-2025)
  • Table 187. India COVID-19 CRISPR Technology, by Service USD Million (2020-2025)
  • Table 188. South Korea COVID-19 CRISPR Technology, by Type USD Million (2020-2025)
  • Table 189. South Korea COVID-19 CRISPR Technology, by End-users USD Million (2020-2025)
  • Table 190. South Korea COVID-19 CRISPR Technology, by Distribution Channel USD Million (2020-2025)
  • Table 191. South Korea COVID-19 CRISPR Technology, by Service USD Million (2020-2025)
  • Table 192. Taiwan COVID-19 CRISPR Technology, by Type USD Million (2020-2025)
  • Table 193. Taiwan COVID-19 CRISPR Technology, by End-users USD Million (2020-2025)
  • Table 194. Taiwan COVID-19 CRISPR Technology, by Distribution Channel USD Million (2020-2025)
  • Table 195. Taiwan COVID-19 CRISPR Technology, by Service USD Million (2020-2025)
  • Table 196. Australia COVID-19 CRISPR Technology, by Type USD Million (2020-2025)
  • Table 197. Australia COVID-19 CRISPR Technology, by End-users USD Million (2020-2025)
  • Table 198. Australia COVID-19 CRISPR Technology, by Distribution Channel USD Million (2020-2025)
  • Table 199. Australia COVID-19 CRISPR Technology, by Service USD Million (2020-2025)
  • Table 200. Rest of Asia-Pacific COVID-19 CRISPR Technology, by Type USD Million (2020-2025)
  • Table 201. Rest of Asia-Pacific COVID-19 CRISPR Technology, by End-users USD Million (2020-2025)
  • Table 202. Rest of Asia-Pacific COVID-19 CRISPR Technology, by Distribution Channel USD Million (2020-2025)
  • Table 203. Rest of Asia-Pacific COVID-19 CRISPR Technology, by Service USD Million (2020-2025)
  • Table 204. Europe COVID-19 CRISPR Technology, by Country USD Million (2020-2025)
  • Table 205. Europe COVID-19 CRISPR Technology, by Type USD Million (2020-2025)
  • Table 206. Europe COVID-19 CRISPR Technology, by End-users USD Million (2020-2025)
  • Table 207. Europe COVID-19 CRISPR Technology, by Distribution Channel USD Million (2020-2025)
  • Table 208. Europe COVID-19 CRISPR Technology, by Service USD Million (2020-2025)
  • Table 209. Germany COVID-19 CRISPR Technology, by Type USD Million (2020-2025)
  • Table 210. Germany COVID-19 CRISPR Technology, by End-users USD Million (2020-2025)
  • Table 211. Germany COVID-19 CRISPR Technology, by Distribution Channel USD Million (2020-2025)
  • Table 212. Germany COVID-19 CRISPR Technology, by Service USD Million (2020-2025)
  • Table 213. France COVID-19 CRISPR Technology, by Type USD Million (2020-2025)
  • Table 214. France COVID-19 CRISPR Technology, by End-users USD Million (2020-2025)
  • Table 215. France COVID-19 CRISPR Technology, by Distribution Channel USD Million (2020-2025)
  • Table 216. France COVID-19 CRISPR Technology, by Service USD Million (2020-2025)
  • Table 217. Italy COVID-19 CRISPR Technology, by Type USD Million (2020-2025)
  • Table 218. Italy COVID-19 CRISPR Technology, by End-users USD Million (2020-2025)
  • Table 219. Italy COVID-19 CRISPR Technology, by Distribution Channel USD Million (2020-2025)
  • Table 220. Italy COVID-19 CRISPR Technology, by Service USD Million (2020-2025)
  • Table 221. United Kingdom COVID-19 CRISPR Technology, by Type USD Million (2020-2025)
  • Table 222. United Kingdom COVID-19 CRISPR Technology, by End-users USD Million (2020-2025)
  • Table 223. United Kingdom COVID-19 CRISPR Technology, by Distribution Channel USD Million (2020-2025)
  • Table 224. United Kingdom COVID-19 CRISPR Technology, by Service USD Million (2020-2025)
  • Table 225. Netherlands COVID-19 CRISPR Technology, by Type USD Million (2020-2025)
  • Table 226. Netherlands COVID-19 CRISPR Technology, by End-users USD Million (2020-2025)
  • Table 227. Netherlands COVID-19 CRISPR Technology, by Distribution Channel USD Million (2020-2025)
  • Table 228. Netherlands COVID-19 CRISPR Technology, by Service USD Million (2020-2025)
  • Table 229. Rest of Europe COVID-19 CRISPR Technology, by Type USD Million (2020-2025)
  • Table 230. Rest of Europe COVID-19 CRISPR Technology, by End-users USD Million (2020-2025)
  • Table 231. Rest of Europe COVID-19 CRISPR Technology, by Distribution Channel USD Million (2020-2025)
  • Table 232. Rest of Europe COVID-19 CRISPR Technology, by Service USD Million (2020-2025)
  • Table 233. MEA COVID-19 CRISPR Technology, by Country USD Million (2020-2025)
  • Table 234. MEA COVID-19 CRISPR Technology, by Type USD Million (2020-2025)
  • Table 235. MEA COVID-19 CRISPR Technology, by End-users USD Million (2020-2025)
  • Table 236. MEA COVID-19 CRISPR Technology, by Distribution Channel USD Million (2020-2025)
  • Table 237. MEA COVID-19 CRISPR Technology, by Service USD Million (2020-2025)
  • Table 238. Middle East COVID-19 CRISPR Technology, by Type USD Million (2020-2025)
  • Table 239. Middle East COVID-19 CRISPR Technology, by End-users USD Million (2020-2025)
  • Table 240. Middle East COVID-19 CRISPR Technology, by Distribution Channel USD Million (2020-2025)
  • Table 241. Middle East COVID-19 CRISPR Technology, by Service USD Million (2020-2025)
  • Table 242. Africa COVID-19 CRISPR Technology, by Type USD Million (2020-2025)
  • Table 243. Africa COVID-19 CRISPR Technology, by End-users USD Million (2020-2025)
  • Table 244. Africa COVID-19 CRISPR Technology, by Distribution Channel USD Million (2020-2025)
  • Table 245. Africa COVID-19 CRISPR Technology, by Service USD Million (2020-2025)
  • Table 246. North America COVID-19 CRISPR Technology, by Country USD Million (2020-2025)
  • Table 247. North America COVID-19 CRISPR Technology, by Type USD Million (2020-2025)
  • Table 248. North America COVID-19 CRISPR Technology, by End-users USD Million (2020-2025)
  • Table 249. North America COVID-19 CRISPR Technology, by Distribution Channel USD Million (2020-2025)
  • Table 250. North America COVID-19 CRISPR Technology, by Service USD Million (2020-2025)
  • Table 251. United States COVID-19 CRISPR Technology, by Type USD Million (2020-2025)
  • Table 252. United States COVID-19 CRISPR Technology, by End-users USD Million (2020-2025)
  • Table 253. United States COVID-19 CRISPR Technology, by Distribution Channel USD Million (2020-2025)
  • Table 254. United States COVID-19 CRISPR Technology, by Service USD Million (2020-2025)
  • Table 255. Canada COVID-19 CRISPR Technology, by Type USD Million (2020-2025)
  • Table 256. Canada COVID-19 CRISPR Technology, by End-users USD Million (2020-2025)
  • Table 257. Canada COVID-19 CRISPR Technology, by Distribution Channel USD Million (2020-2025)
  • Table 258. Canada COVID-19 CRISPR Technology, by Service USD Million (2020-2025)
  • Table 259. Mexico COVID-19 CRISPR Technology, by Type USD Million (2020-2025)
  • Table 260. Mexico COVID-19 CRISPR Technology, by End-users USD Million (2020-2025)
  • Table 261. Mexico COVID-19 CRISPR Technology, by Distribution Channel USD Million (2020-2025)
  • Table 262. Mexico COVID-19 CRISPR Technology, by Service USD Million (2020-2025)
  • Table 263. Research Programs/Design for This Report
  • Table 264. Key Data Information from Secondary Sources
  • Table 265. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global COVID-19 CRISPR Technology: by Type USD Million (2014-2019)
  • Figure 5. Global COVID-19 CRISPR Technology: by End-users USD Million (2014-2019)
  • Figure 6. Global COVID-19 CRISPR Technology: by Distribution Channel USD Million (2014-2019)
  • Figure 7. Global COVID-19 CRISPR Technology: by Service USD Million (2014-2019)
  • Figure 8. South America COVID-19 CRISPR Technology Share (%), by Country
  • Figure 9. Asia Pacific COVID-19 CRISPR Technology Share (%), by Country
  • Figure 10. Europe COVID-19 CRISPR Technology Share (%), by Country
  • Figure 11. MEA COVID-19 CRISPR Technology Share (%), by Country
  • Figure 12. North America COVID-19 CRISPR Technology Share (%), by Country
  • Figure 13. Global COVID-19 CRISPR Technology share by Players 2019 (%)
  • Figure 14. Global COVID-19 CRISPR Technology share by Players (Top 3) 2019(%)
  • Figure 15. Global COVID-19 CRISPR Technology share by Players (Top 5) 2019(%)
  • Figure 16. BCG Matrix for key Companies
  • Figure 17. Thermo Fisher Scientific (United States) Revenue, Net Income and Gross profit
  • Figure 18. Thermo Fisher Scientific (United States) Revenue: by Geography 2019
  • Figure 19. Merck KGaA (Germany) Revenue, Net Income and Gross profit
  • Figure 20. Merck KGaA (Germany) Revenue: by Geography 2019
  • Figure 21. Genscript Biotech (United States) Revenue, Net Income and Gross profit
  • Figure 22. Genscript Biotech (United States) Revenue: by Geography 2019
  • Figure 23. Integrated DNA Technologies, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 24. Integrated DNA Technologies, Inc. (United States) Revenue: by Geography 2019
  • Figure 25. Horizon Discovery Group (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 26. Horizon Discovery Group (United Kingdom) Revenue: by Geography 2019
  • Figure 27. Agilent Technologies (United States) Revenue, Net Income and Gross profit
  • Figure 28. Agilent Technologies (United States) Revenue: by Geography 2019
  • Figure 29. Cellecta, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 30. Cellecta, Inc. (United States) Revenue: by Geography 2019
  • Figure 31. GeneCopoeia, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 32. GeneCopoeia, Inc. (United States) Revenue: by Geography 2019
  • Figure 33. New England Biolabs (United States) Revenue, Net Income and Gross profit
  • Figure 34. New England Biolabs (United States) Revenue: by Geography 2019
  • Figure 35. Origene Technologies, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 36. Origene Technologies, Inc. (United States) Revenue: by Geography 2019
  • Figure 37. Global COVID-19 CRISPR Technology: by Type USD Million (2020-2025)
  • Figure 38. Global COVID-19 CRISPR Technology: by End-users USD Million (2020-2025)
  • Figure 39. Global COVID-19 CRISPR Technology: by Distribution Channel USD Million (2020-2025)
  • Figure 40. Global COVID-19 CRISPR Technology: by Service USD Million (2020-2025)
  • Figure 41. South America COVID-19 CRISPR Technology Share (%), by Country
  • Figure 42. Asia Pacific COVID-19 CRISPR Technology Share (%), by Country
  • Figure 43. Europe COVID-19 CRISPR Technology Share (%), by Country
  • Figure 44. MEA COVID-19 CRISPR Technology Share (%), by Country
  • Figure 45. North America COVID-19 CRISPR Technology Share (%), by Country
Some of the key companies/manufacturers profiled in the report
  • Thermo Fisher Scientific (United States)
  • Merck KGaA (Germany)
  • Genscript Biotech (United States)
  • Integrated DNA Technologies, Inc. (United States)
  • Horizon Discovery Group (United Kingdom)
  • Agilent Technologies (United States)
  • Cellecta, Inc. (United States)
  • GeneCopoeia, Inc. (United States)
  • New England Biolabs (United States)
  • Origene Technologies, Inc. (United States)
Additional players considered in the study are as follows:
Synthego Corporation (United States) , Toolgen, Inc. (South Korea)
Select License Type
Sample Report Enquiry Before Buy Request Discount

Speak with Analyst

Want to find out more about this report?

Get Free Consultation